Our Pipeline

Pipeline

Advancing differentiated assets from commercialization through clinical development

Oleolive is building a portfolio across nutrition, oncology, neurology, fibrosis, and acute care.

Commercialized

Discovery

Preclinical

IND Enabling

Phase 1

Oligen®

Dietary ingredient

Commercialized novel olive polyphenol flagship ingredient with partner Applied Food Sciences.

OL TL1

Glioblastoma

TROY targeting therapeutic designed to sensitize GBM tumors to radiotherapy and temozolomide.

OL 003

Alzheimer’s disease

Dual PPAR delta and gamma agonist targeting neuroinflammation, insulin resistance, and metabolic dysfunction.

OL JC2

Pulmonary fibrosis

Inhalable Casein Kinase 1 alpha agonist designed to block TGFβ driven fibrosis while minimizing systemic side effects.

Agile PRP

Non compressible hemorrhage

Lyophilized platelet rich plasma platform intended for rapid field deployment in trauma settings.

Portfolio shown for presentation purposes. Stage definitions can be adjusted as programs advance.